Edwards Lifesciences Corporation (EW) key performance indicators and operating metrics (28 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Adjusted Earnings per Share, Diluted (Non-GAAP) | 0.78 USD_per_share | FY2026-Q1 |
| Global Transcatheter Aortic Valve Replacement Sales | 1.2B | FY2026-Q1 |
| Adjusted Operating Profit Margin (Non-GAAP) | 31.40 percent | FY2026-Q1 |
| Adjusted Gross Profit Margin (Non-GAAP) | 78.20 percent | FY2026-Q1 |
| Transcatheter Mitral and Tricuspid Therapies Sales | 173M | FY2026-Q1 |
| Transcatheter Aortic Valve Replacement Sales Growth Constant Currency | 11.00 percent | FY2026-Q1 |
| Surgical Sales (Continuing Operations) | 276M | FY2026-Q1 |
| Total Company Sales Growth (Constant Currency) | 12.70 percent | FY2026-Q1 |
| Total Company Sales Growth Year over Year (Reported) | 16.70 percent | FY2026-Q1 |
| Surgical Sales Growth Year over Year | 6.00 percent | FY2026-Q1 |
| Transcatheter Mitral and Tricuspid Therapies Sales Growth | 42.00 percent | FY2026-Q1 |
| Underlying Sales Growth (Self-Growth) | 12.70 percent | FY2026-Q1 |
| Transcatheter Aortic Valve Replacement Sales Growth Year over Year (Reported) | 10.60 percent | FY2025-Q4 |
| Total Company Sales Growth (Adjusted) | 12.60 percent | FY2025-Q3 |
Back to EW overview · EW earnings · EW holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.